Filtered By:
Condition: Disability
Therapy: Thrombolytic Therapy

This page shows you your search results in order of relevance. This is page number 5.

Order by Relevance | Date

Total 183 results found since Jan 2013.

RCT: Endovascular treatment for acute ischaemic stroke
Source: NEJM Area: News A study, published in New England Journal of Medicine, compares the clinical efficacy of endovascular treatment with systemic intravenous thrombolytic therapy in patients with ischaemic stroke.   The study randomly assigned 362 patients with acute ischemic stroke, within 4.5 hours after onset, to endovascular therapy (intra-arterial thrombolysis with recombinant tissue plasminogen activator [t-PA], mechanical clot disruption or retrieval, or a combination of these approaches) (181 patients) or intravenous t-PA (181 patients). Treatments were to be given as soon as possible after randomisat...
Source: NeLM - News - February 8, 2013 Category: Drugs & Pharmacology Source Type: news

Case series of post-thrombolysis patients undergoing hemicraniectomy for malignant anterior circulation ischaemic stroke.
Authors: Williams A, Sittampalam M, Barua N, Mohd Nor A Abstract While ischaemic stroke remains a leading cause of death and disability, there have been recent advancements in treatment modalities including thrombolysis and decompressive hemicraniectomy. A retrospective review of patients treated in our NHS teaching hospital, in Plymouth (UK), over a 2 year period identified 17 thrombolysed patients, of whom two had undergone subsequent decompressive hemicraniectomy. These were non-dominant hemisphere strokes in young patients, aged 51 and 57. Initial NIHSS scores were 16 and 17, and they received thrombolysis at 2...
Source: Cardiovascular Psychiatry and Neurology - November 25, 2014 Category: Psychiatry Tags: Cardiovasc Psychiatry Neurol Source Type: research

Anti-inflammatory Target of a Novel Thrombolytic Stroke Drug Enzymology
Although ischemic stroke is a major cause of death and disability worldwide, only a small fraction of patients benefit from the current thrombolytic therapy due to a risk of cerebral hemorrhage caused by inflammation. Thus, the development of a new strategy to combat inflammation during thrombolysis is an urgent demand. The small molecule thrombolytic SMTP-7 effectively treats ischemic stroke in several animal models with reducing cerebral hemorrhage. Here we revealed that SMTP-7 targeted soluble epoxide hydrolase (sEH) to suppress inflammation. SMTP-7 inhibited both of the two sEH enzyme activities: epoxide hydrolase (whi...
Source: Journal of Biological Chemistry - December 26, 2014 Category: Chemistry Authors: Matsumoto, N., Suzuki, E., Ishikawa, M., Shirafuji, T., Hasumi, K. Tags: Enzymology Source Type: research

Reperfusion Therapies in Acute Ischemic Stroke.
Authors: Yeo LL, Tan BY, Yee W, Amit K, Sharma VK Abstract Acute Ischemic stroke (IS) remains a leading cause of mortality and long-term disability. Owing to the time-constraints, only a fraction of acute IS patients receive the established and approved thrombolytic therapy and a sizeable proportion of acute IS stroke survivors remain permanently disabled. Rapid advances in various recanalization strategies have aimed at improving functional outcome and reducing mortality. Existing literature on various treatment approaches, including the evolution of various thrombolytic agents and interventional devices is presen...
Source: Recent Patents on CNS Drug Discovery - July 3, 2015 Category: Drugs & Pharmacology Tags: Recent Pat CNS Drug Discov Source Type: research

Interventional Cardiologists in the Treatment of Acute Ischemic Stroke: New Players in the Game
Ischemic stroke is a devastating condition with a high burden of neurologic disability and death. Multiple randomized controlled trials have shown the efficacy of intravenous thrombolysis up to 4.5hours from onset in patients with acute ischemic stroke (1). However, the utility and efficacy of thrombolytic therapy in acute stroke management is limited by a narrow time window for treatment, thrombus burden and patient related thrombolytic contraindications (2,3).
Source: International Journal of Cardiology - September 25, 2015 Category: Cardiology Authors: Mehmet Ergelen, Huseyin Uyarel Source Type: research

Using a Quality Improvement Process to Create Measurable Improvement in Care Delivery for Acute Stroke
The introduction of thrombolytic therapy has revolutionized the management of acute ischemic stroke, and it has now been conclusively established that tissue plasminogen activator (t-PA) given within 4.5 hours of stroke onset both limits irreversible ischemic neuronal damage by establishing reperfusion of the penumbra and improves outcomes for patients who have undergone stroke. Clinical trials have demonstrated that in patients who receive t-PA, there is a reduction in disability and a greater chance of having significant recovery (Wardlaw et al. 2009).
Source: Healthcare Quarterly - July 25, 2011 Category: Global & Universal Source Type: research

The application of pre-hospital first aid mode in patients with acute stroke: meta-analysis
Folia Neuropathol. 2022;60(3):284-291. doi: 10.5114/fn.2022.117614.ABSTRACTTo systematically evaluate the application effect of pre-hospital and in-hospital emergency mode in patients with acute stroke. The study was conducted by systematic search of Chinese (CNKI, Wanfang and VIP) and English (PubMed, EMBASE and Cochrane Library) databases. The case-control studies comparing the role of pre-hospital and in-hospital emergency mode for patients with acute stroke were included in this study. Outcome indicators included the time from admission to thrombolytic therapy (DNT), the time from calling for help to receiving professi...
Source: Folia Neuropathologica - November 16, 2022 Category: Pathology Authors: Xiaoting Zhu Rong Niu Fangfang Bai Zhufeng Zhang Source Type: research